EFC6596 (CINJ 070703): A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen.

Trial Profile

EFC6596 (CINJ 070703): A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2016

At a glance

  • Drugs Capecitabine; Fluorouracil; Larotaxel
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PAPRIKA
  • Most Recent Events

    • 30 Jun 2010 Actual patient number added.
    • 30 Jun 2010 Results were presented at the 12th World Congress on Gastrointestinal Cancer (2010).
    • 29 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top